Literature DB >> 18160019

Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains.

Susan H Eshleman1, Sarah E Hudelson, Robert Bruce, Travis Lee, Michelle R Owens, John Hackett, Priscilla Swanson, Sushil G Devare, Natalia Marlowe.   

Abstract

The HIV fusion inhibitor enfuvirtide (ENF/Fuzeon) targets the env gp41 transmembrane domain. Mutations in gp41 are associated with ENF resistance. We developed a prototype assay to genotype a 676-bp region spanning the heptad repeat domains (HR1 and HR2) of HIV-1 gp41. Plasma samples were collected from 126 HIV-1-infected blood donors in Cameroon, Brazil, Uganda, South Africa, Thailand, and Argentina. Based on analysis of gag p24, pol integrase, and env gp41 genes, the panel was composed of subtypes A/A2 (18), B (11), C (14), D (10), F/F2 (9), G (7), CRF01_AE (9), CRF02_AG (33), and recombinant strains (15). Genotyping was successful for 119 of the 126 samples (94.4%). Although numerous amino acid polymorphisms were detected in some samples, none had primary mutations associated with ENF resistance. The gp41 HIV-1 research reagents developed by Celera are useful tools for genotyping analysis of the gp41 region in diverse HIV-1 strains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160019     DOI: 10.1089/aid.2007.0130

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

Authors:  Kazuki Izumi; Kumi Kawaji; Fusasko Miyamoto; Kazuki Shimane; Kazuya Shimura; Yasuko Sakagami; Toshio Hattori; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Int J Biochem Cell Biol       Date:  2013-01-26       Impact factor: 5.085

2.  Appreciating HIV type 1 diversity: subtype differences in Env.

Authors:  Rebecca M Lynch; Tongye Shen; S Gnanakaran; Cynthia A Derdeyn
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

3.  HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide.

Authors:  Neelanjana Ray; Leslie A Blackburn; Robert W Doms
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

4.  Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors.

Authors:  Sarah E Hudelson; Natalia Marlowe; Wei Huang; Robert Bruce; Jessica D Church; Marla Husnik; Deborah Donnell; Thomas Coates; J Brooks Jackson; Margaret Chesney; Beryl Koblin; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2009-07       Impact factor: 2.205

5.  Risk of heterosexual HIV transmission attributable to sexually transmitted infections and non-specific genital inflammation in Zambian discordant couples, 1994-2012.

Authors:  Kristin M Wall; William Kilembe; Bellington Vwalika; Lisa B Haddad; Eric Hunter; Shabir Lakhi; Roy Chavuma; Naw Htee Khu; Ilene Brill; Cheswa Vwalika; Lawrence Mwananyanda; Elwyn Chomba; Joseph Mulenga; Amanda Tichacek; Susan Allen
Journal:  Int J Epidemiol       Date:  2017-10-01       Impact factor: 7.196

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.